Réka Skoda, Vencel Juhász, Zsófia Dohy, Anita Pintér, Laura Bokor, György Bárczi, Hajnalka Vágó, Béla Merkely, Dávid Becker
{"title":"The effect of COVID-19 pandemic on myocardial infarction care and on its prognosis - Experience at a high volume Hungarian cardiovascular center.","authors":"Réka Skoda, Vencel Juhász, Zsófia Dohy, Anita Pintér, Laura Bokor, György Bárczi, Hajnalka Vágó, Béla Merkely, Dávid Becker","doi":"10.1556/2060.2022.00083","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The COVID-19 pandemic has impacted many aspects of acute myocardial infarction. Based on literature data, the prognosis of COVID+, STEMI patients is significantly worse than that of COVID- STEMI patients. On the other hand, physicians report fewer acute coronary syndrome (ACS) patients presenting to hospitals in countries severely affected by the pandemic. It is concerning that patients with life-threatening illness can suffer more complications or die due to their myocardial infarction. We aimed to investigate the changes in myocardial infarction care in the country's biggest PCI-center and to compare total 30-day mortality in COVID+ and COVID-patients with acute myocardial infarction treated at the Semmelweis University Heart and Vascular Center, and to investigate risk factors and complications in these two groups.</p><p><strong>Methods: </strong>Between 8 October 2020 and 30 April 2021, 43 COVID+, in 2018-2019, 397 COVID-patients with acute myocardial infarction were admitted. Total admission rates pre- and during the pandemic were compared.</p><p><strong>Results: </strong>Within 30 days, 8 of 43 patients in the COVID+ group (18.60%), and 40 of the 397 patients in the control group (10.07%) died (P = 0.01). Regarding the comorbidities, more than half of COVID+ patients had a significantly reduced ejection fraction (EF≤ 40%), and the prevalence of heart failure was significantly higher in this group (51.16% vs. 27.84%, P = 0.0329). There was no significant difference between the two patient groups in the incidence of STEMI and NSTEMI. Although there was no significant difference, VF (11.63% vs. 6.82%), resuscitation (23.26% vs. 10.08%), and ECMO implantation (2.38% vs. 1.26%) were more common in the COVID+ group. The mean age was 68.8 years in the COVID+ group and 67.6 years in the control group. The max. Troponin also did not differ significantly between the two groups (1,620 vs. 1,470 ng/L). There was a significant decline in admission rates in the first as well as in the second wave of the pandemic.</p><p><strong>Conclusions: </strong>The 30-day total mortality of COVID+ patients was significantly higher, and a more severe proceeding of acute myocardial infarction and a higher incidence of complications can be observed. As the secondary negative effect of the pandemic serious decline in admission rates can be detected.</p>","PeriodicalId":20058,"journal":{"name":"Physiology international","volume":"109 3","pages":"419-426"},"PeriodicalIF":2.2000,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Physiology international","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1556/2060.2022.00083","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/12 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The COVID-19 pandemic has impacted many aspects of acute myocardial infarction. Based on literature data, the prognosis of COVID+, STEMI patients is significantly worse than that of COVID- STEMI patients. On the other hand, physicians report fewer acute coronary syndrome (ACS) patients presenting to hospitals in countries severely affected by the pandemic. It is concerning that patients with life-threatening illness can suffer more complications or die due to their myocardial infarction. We aimed to investigate the changes in myocardial infarction care in the country's biggest PCI-center and to compare total 30-day mortality in COVID+ and COVID-patients with acute myocardial infarction treated at the Semmelweis University Heart and Vascular Center, and to investigate risk factors and complications in these two groups.
Methods: Between 8 October 2020 and 30 April 2021, 43 COVID+, in 2018-2019, 397 COVID-patients with acute myocardial infarction were admitted. Total admission rates pre- and during the pandemic were compared.
Results: Within 30 days, 8 of 43 patients in the COVID+ group (18.60%), and 40 of the 397 patients in the control group (10.07%) died (P = 0.01). Regarding the comorbidities, more than half of COVID+ patients had a significantly reduced ejection fraction (EF≤ 40%), and the prevalence of heart failure was significantly higher in this group (51.16% vs. 27.84%, P = 0.0329). There was no significant difference between the two patient groups in the incidence of STEMI and NSTEMI. Although there was no significant difference, VF (11.63% vs. 6.82%), resuscitation (23.26% vs. 10.08%), and ECMO implantation (2.38% vs. 1.26%) were more common in the COVID+ group. The mean age was 68.8 years in the COVID+ group and 67.6 years in the control group. The max. Troponin also did not differ significantly between the two groups (1,620 vs. 1,470 ng/L). There was a significant decline in admission rates in the first as well as in the second wave of the pandemic.
Conclusions: The 30-day total mortality of COVID+ patients was significantly higher, and a more severe proceeding of acute myocardial infarction and a higher incidence of complications can be observed. As the secondary negative effect of the pandemic serious decline in admission rates can be detected.
新冠肺炎疫情对急性心肌梗死的诸多方面产生了影响。根据文献资料,COVID+、STEMI患者的预后明显差于COVID- STEMI患者。另一方面,在受疫情严重影响的国家,医生报告到医院就诊的急性冠状动脉综合征(ACS)患者较少。令人担忧的是,患有危及生命的疾病的患者可能会出现更多的并发症或因心肌梗死而死亡。我们的目的是调查该国最大的pci中心心肌梗死护理的变化,并比较在塞梅维什大学心脏和血管中心治疗的COVID+和COVID- 19急性心肌梗死患者的30天总死亡率,并调查这两组的危险因素和并发症。方法:在2020年10月8日至2021年4月30日期间,共收治43例COVID+患者,2018-2019年共收治397例急性心肌梗死患者。对大流行前和大流行期间的总住院率进行比较。结果:30 d内,新冠肺炎+组43例患者中有8例(18.60%)死亡,对照组397例患者中有40例(10.07%)死亡(P = 0.01)。在合并症方面,超过一半的COVID+患者射血分数明显降低(EF≤40%),心力衰竭发生率明显高于对照组(51.16% vs. 27.84%, P = 0.0329)。两组患者在STEMI和NSTEMI发生率上无显著差异。虽然无显著差异,但VF (11.63% vs. 6.82%)、复苏(23.26% vs. 10.08%)和ECMO植入(2.38% vs. 1.26%)在COVID+组更为常见。新冠肺炎+组平均年龄为68.8岁,对照组平均年龄为67.6岁。马克斯。肌钙蛋白在两组之间也没有显著差异(1,620 vs 1,470 ng/L)。在大流行的第一波和第二波中,入院率显著下降。结论:新型冠状病毒感染患者30天总死亡率明显增高,急性心肌梗死进展更严重,并发症发生率更高。作为大流行的次要负面影响,可以发现入院率严重下降。
期刊介绍:
The journal provides a forum for important new research papers written by eminent scientists on experimental medical sciences. Papers reporting on both original work and review articles in the fields of basic and clinical physiology, pathophysiology (from the subcellular organization level up to the oranizmic one), as well as related disciplines, including history of physiological sciences, are accepted.